These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 11439734

  • 1. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
    Ehrich EW, Bolognese JA, Watson DJ, Kong SX.
    Am J Manag Care; 2001 Jun; 7(6):609-16. PubMed ID: 11439734
    [Abstract] [Full Text] [Related]

  • 2. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A, Williams GW, McKenna F, Fort JG.
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [Abstract] [Full Text] [Related]

  • 3. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
    Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N.
    J Rheumatol; 2000 Nov; 27(11):2635-41. PubMed ID: 11093446
    [Abstract] [Full Text] [Related]

  • 4. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A, Ma C, Ahdieh H, Galer BS.
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [Abstract] [Full Text] [Related]

  • 5. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.
    J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [Abstract] [Full Text] [Related]

  • 7. Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial.
    Lambert RG, Hutchings EJ, Grace MG, Jhangri GS, Conner-Spady B, Maksymowych WP.
    Arthritis Rheum; 2007 Jul; 56(7):2278-87. PubMed ID: 17599747
    [Abstract] [Full Text] [Related]

  • 8. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
    Detora LM, Krupa D, Bolognese J, Sperling RS, Ehrich EW.
    J Rheumatol; 2001 Nov; 28(11):2494-503. PubMed ID: 11708424
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
    Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M, CAPSS-114 Study Group.
    J Rheumatol; 2004 Jan; 31(1):150-6. PubMed ID: 14705234
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP, VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups.
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [Abstract] [Full Text] [Related]

  • 11. Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints.
    Bolognese JA, Ehrich EW, Schnitzer TJ.
    J Rheumatol; 2001 Dec; 28(12):2700-4. PubMed ID: 11764220
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
    Schnitzer TJ, Kivitz AJ, Lipetz RS, Sanders N, Hee A.
    Arthritis Rheum; 2005 Dec 15; 53(6):827-37. PubMed ID: 16342089
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial).
    Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P.
    Semin Arthritis Rheum; 2009 Aug 15; 39(1):1-9. PubMed ID: 19539353
    [Abstract] [Full Text] [Related]

  • 14. Assessment of health-related quality of life after surgical treatment of focal symptomatic spinal stenosis compared with osteoarthritis of the hip or knee.
    Rampersaud YR, Ravi B, Lewis SJ, Stas V, Barron R, Davey R, Mahomed N.
    Spine J; 2008 Aug 15; 8(2):296-304. PubMed ID: 17669690
    [Abstract] [Full Text] [Related]

  • 15. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
    Smugar SS, Schnitzer TJ, Weaver AL, Rubin BR, Polis AB, Tershakovec AM.
    Curr Med Res Opin; 2006 Jul 15; 22(7):1353-67. PubMed ID: 16834834
    [Abstract] [Full Text] [Related]

  • 16. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 17. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C, Sindet-Pederson S, Seymour RA, Hawkesford JE, Coulthard P, Lamey PJ, Gerry Cowan C, Wickens M, Jeppsson L, Dean AD, Svensson O.
    Clin Ther; 2006 Sep 24; 28(9):1279-95. PubMed ID: 17062301
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
    Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, Gimbel J, Coleman S, Fisher C, Nabizadeh S, Borenstein D, Vioxx Chronic Low Back Pain Study Group.
    Spine (Phila Pa 1976); 2003 May 01; 28(9):851-8; discussion 859. PubMed ID: 12941996
    [Abstract] [Full Text] [Related]

  • 19. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients.
    Vorsanger G, Xiang J, Jordan D, Farrell J.
    Clin Ther; 2007 May 01; 29 Suppl():2520-35. PubMed ID: 18164919
    [Abstract] [Full Text] [Related]

  • 20. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
    Matsumoto AK, Babul N, Ahdieh H.
    Pain Med; 2005 May 01; 6(5):357-66. PubMed ID: 16266356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.